Review
Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies
Perfil de efectividad y seguridad de tenapanor, un inhibidor de la isoforma 3 del intercambiador de sodio/hidrógeno, como tratamiento innovador para la hiperfosfatemia en la enfermedad renal crónica, una revisión sistemática de estudios clínicos
William Suciangtoa,
, Haerani Rasyidb, Anastasya Angelica Vicentec, Winny Suciangtoa
Corresponding author
a Department of Medical Doctor Study Program, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia
b Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia
c Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia
Read
4093
Timeswas read the article
1203
Total PDF
2890
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 11 | 163 | 61 | 224 |
| 2025 10 | 154 | 69 | 223 |
| 2025 9 | 196 | 78 | 274 |
| 2025 8 | 196 | 137 | 333 |
| 2025 7 | 132 | 38 | 170 |
| 2025 6 | 213 | 127 | 340 |
| 2025 5 | 175 | 70 | 245 |
| 2025 4 | 134 | 25 | 159 |
| 2025 3 | 158 | 68 | 226 |
| 2025 2 | 150 | 48 | 198 |
| 2025 1 | 145 | 64 | 209 |
| 2024 12 | 169 | 57 | 226 |
| 2024 11 | 381 | 77 | 458 |
| 2024 10 | 108 | 60 | 168 |
| 2024 9 | 147 | 51 | 198 |
| 2024 8 | 138 | 78 | 216 |
| 2024 7 | 97 | 36 | 133 |
| 2024 6 | 34 | 59 | 93 |
Show all
